Finasteride vs. Dutasteride: Which Should You Take for Hair Loss?

Both drugs block DHT, the androgen that drives pattern hair loss. The TL;DR: dutasteride is more potent and produces somewhat more regrowth in head-to-head trials, but it’s off-label for hair loss in most countries, has a longer half-life, and has somewhat more pronounced side effects. Finasteride is FDA-approved and the more standard first-line choice. Combination with minoxidil outperforms either drug alone.

This guide covers what each drug actually does, the head-to-head efficacy data, the side-effect profiles (including the controversial “post-finasteride syndrome”), and how dermatologists actually choose between them.

What these drugs actually do

Both drugs inhibit 5α-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is the androgen that drives the miniaturisation of hair follicles in androgenetic alopecia. Less DHT means less miniaturisation pressure and, in many men, partial reversal of follicle shrinkage.

The difference is which form of the enzyme each drug targets:

• Finasteride inhibits type II 5α-reductase (the dominant form in the scalp and prostate). At 1 mg/day, it reduces scalp DHT by roughly 60–70% and serum DHT by around 70%.
• Dutasteride inhibits both type I and type II 5α-reductase. At 0.5 mg/day, it reduces serum DHT by around 90%, a more complete blockade than finasteride.

The more complete DHT suppression is why dutasteride produces somewhat better cosmetic outcomes in trials. It’s also why side-effect rates trend higher.

What the trials show

Finasteride (5-year data)

The most-quoted finasteride study is the Kaufman et al. 2002 long-term extension, which followed men on finasteride 1 mg for 5 years¹ :

• 48% saw improved hair count at year 5 versus baseline
• 42% saw stabilisation (no further loss)
• 10% experienced continued loss despite treatment
• Combined: roughly 90% of men maintained or improved their hair on finasteride over 5 years¹

The placebo arm, by contrast, showed continued progressive loss, meaning finasteride changed the trajectory in about 9 in 10 men.

Dutasteride

Dutasteride is FDA-approved for benign prostatic hyperplasia (BPH), not hair loss, in most countries. In South Korea and Japan, it’s approved for AGA. Off-label use for hair loss is widespread elsewhere.

In the Olsen et al. 2006 head-to-head trial comparing dutasteride 0.5 mg vs. finasteride 5 mg vs. placebo over 24 weeks (note: the 5 mg finasteride dose was higher than the standard 1 mg used for hair loss)² :

• Dutasteride 0.5 mg produced greater hair count and width improvements than either finasteride 5 mg or placebo.

Subsequent studies have generally shown dutasteride 0.5 mg producing modestly greater cosmetic improvement than finasteride 1 mg, with the difference more pronounced in advanced cases.

Head-to-head comparison

Side effects, honestly

Sexual side effects

The most-discussed and most-feared category. In randomised trials, sexual side effects (decreased libido, erectile dysfunction, ejaculatory issues) occurred in roughly:

• Finasteride: ~2–4% of users versus ~1–2% on placebo
• Dutasteride: somewhat higher rates than finasteride in head-to-head data

A few important nuances:

• Most are reversible. In the majority of men who experience sexual side effects, they resolve after stopping the drug, often within weeks to months.
• Real-world rates may be higher than RCT rates. Some observational studies and post-marketing reports suggest higher rates than the clinical trials, possibly because of the “nocebo” effect (expecting side effects increases reported rates) or selection biases in self-reported data.
• The relationship between dose and side effects is not linear. Finasteride 1 mg has roughly the same sexual side effect profile as finasteride 5 mg in BPH studies, suggesting near-maximal effect at the lower hair-loss dose.

Post-finasteride syndrome (PFS)

A controversial entity. PFS is described in some patients as persistent sexual, neurological, and emotional symptoms that continue after stopping finasteride, sometimes for years³ .

The honest summary of the evidence:

• The phenomenon is real for some patients. Persistent post-treatment symptoms are documented in case series and some prospective data.
• The frequency is contested. Estimates range from rare to several percent of users, depending on methodology and definition.
• The mechanism is unclear. Theories involve neurosteroid disruption, persistent epigenetic changes, or psychological factors; none are conclusively established.
• Risk factors appear to include younger age at treatment, longer duration of use, and pre-existing mental health conditions, but the evidence here is observational.

What this means practically: the risk is small in absolute terms but nonzero. Anyone considering finasteride should be aware of PFS, discuss it with the prescribing doctor, and stop the drug if persistent unusual symptoms appear.

Other side effects

• Gynecomastia (breast enlargement or tenderness). Uncommon, dose-related.
• Depression and mood changes. Reported in a small percentage of users; the causal relationship is debated.
• Reduced semen volume. Common but not typically clinically significant.
• Effect on PSA: both drugs reduce PSA (a prostate cancer screening marker) by roughly 50%. Important for any man undergoing prostate cancer screening on these drugs, since the result needs to be doubled for interpretation.

Hard contraindications

• Pregnancy. Both drugs cause severe birth defects in male fetuses. Women of reproductive age should not take them, and women who are or might become pregnant should not handle broken or crushed tablets. This is not a soft warning. It’s a categorical contraindication.
• Allergy to either drug.
• Severe hepatic impairment. Both drugs are metabolised in the liver.

What about topical finasteride?

Topical finasteride has emerged as a way to get the hair-loss benefits with reduced systemic exposure. The 2022 Piraccini et al. phase III trial showed topical finasteride spray 0.25% applied once daily (1 to 4 sprays, 50 to 200 µL depending on the extent of hair loss) produced hair count improvements comparable to oral finasteride 1 mg, with lower serum drug levels and a different side-effect profile⁴ .

The case for topical:

• Lower systemic exposure in studies (though not zero, since measurable serum levels still occur)
• Possibly fewer sexual side effects (early data; trials are smaller than oral finasteride)
• Same efficacy ballpark as oral finasteride 1 mg in head-to-head data

The case against:

• Less long-term data than the decades of oral finasteride experience
• Compounded formulations vary widely in concentration and quality; commercial formulations are still limited in many markets
• Daily application has adherence challenges similar to other topical scalp treatments, though once-daily dosing is easier than twice-daily topical minoxidil

For men who want to try a 5α-reductase inhibitor but are concerned about systemic side effects, topical finasteride is increasingly a reasonable middle-ground option that a dermatologist can prescribe.

How dermatologists actually choose

A practical decision framework:

• First-line for new starters: oral finasteride 1 mg/day. FDA-approved, decades of data, well-tolerated by most men.
• If finasteride isn’t producing adequate effect after 12 months: consider switching to dutasteride (off-label) for the more potent DHT suppression.
• If concerned about systemic side effects: consider topical finasteride as an alternative to oral.
• If experiencing side effects on finasteride that resolve on stopping: depends on how problematic and the patient’s priorities. Some clinicians try a lower dose (1 mg every other day) or topical; some switch to dutasteride; some discontinue and rely on minoxidil alone.

For all of these, combining with topical minoxidil outperforms either drug alone. The two work via different mechanisms (DHT blockade + anagen prolongation) and most dermatologists recommend the combination for men with progressive AGA.

When to see a dermatologist

• You’re considering starting a 5α-reductase inhibitor for the first time
• You’re experiencing side effects on finasteride and considering switching
• You’re considering dutasteride (it’s off-label for hair loss)
• You’re considering topical finasteride
• You have any history of depression, mood disorder, or sexual dysfunction prior to starting, which is relevant to the risk-benefit conversation
• You’re undergoing or due for prostate cancer screening, since finasteride/dutasteride affect PSA interpretation

What this article doesn’t cover

We’ve focused on oral finasteride and dutasteride for male androgenetic alopecia. We’ve left out their off-label use in transgender feminizing hormone therapy (where 5α-reductase inhibitors are sometimes used as a secondary anti-androgen alongside spironolactone, or to treat hair loss in trans women already on estrogen), the off-label use of finasteride in postmenopausal women for FPHL (covered briefly in our female pattern hair loss guide), and the use of these drugs in BPH, which has different dosing considerations.

If hair loss is affecting your wellbeing, talk to a GP or dermatologist sooner rather than later. The 5α-reductase inhibitors are powerful drugs that work, but they’re prescription drugs for a reason, and the risk-benefit conversation is best had with someone who knows your full medical context. Anything in this article is general education, not personal medical advice.